EASD 2009: Lantus defended amid allegations of increased cancer risk
It presenters at the conference discussed the current evidence and its limitations. However, a potential mechanism by which insulin could promote cancer cell growth was also proposed. ( http://www.bharatbook.com/detail.asp?id=91847&rt=Commercial-Insight-Cardiovascular-and-Metabolic-Market-Overview-Diabetes-to-the-fore-as-generics-hit-primary-care-markets.html )
Although the European Association for the Study of Diabetes (EASD) recommended the continued use of Lantus in type 1 and type 2 diabetics, it has called for increased research into the relationship between insulin therapy – particularly Lantus (insulin glargine; Sanofi-Aventis) – and the risk of cancer.
It was postulated during the discussion at the 2009 EASD meeting that insulin use may be related to the increased incidence of cancer seen in diabetics over that seen in the general population. The preliminary data discussed in the symposium suggested lower rates of cancer with Levemir (insulin detemir; Novo Nordisk) compared to neutral protamine Hagedorn (NPH), but higher rates with Lantus. Continue reading ‘EASD 2009 – Lantus defended amid allegations of increased cancer risk’ »
Posted by Christopher Kuntz on June 12, 2010 at 12:22 am under Cancer.
Tags: Aggregator, clinical trial, demand forecast, Health, market, market forecast, market growth, market leaders, market report, market research, market research reports, market share, Medical, pharma, Report, research
Comments Off.
Liver Cancer – Drug Pipeline Analysis and Market Forecasts to 2016
This is an essential source of information and analysis on the global liver cancer market. The report identifies the key trends shaping and driving the global liver cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global liver cancer sector. ( http://www.bharatbook.com/detail.asp?id=134332&rt=Liver-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html ) Continue reading ‘Liver Cancer Market Is Very Strong With Clinical Development’ »
Incoming search terms:
Posted by Christopher Kuntz on April 22, 2010 at 1:29 am under Cancer.
Tags: demand forecast, Drugs, Liver Cancer, market, market forecast, market growth, market leaders, market report, market research, market research reports, market share, pharma, Report, research
Comments Off.